Has Amir Lavaf, MD received payments from drug or device companies?

Yes. Drug and device makers reported $411,491 in general payments to Amir Lavaf, MD across 614 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amir Lavaf, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amir Lavaf, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amir Lavaf, MD

Radiation Oncology · Palm Springs, CANPI 1508024852

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Medtronic at 37.5% of the total. Reporting peaked in 2022 at $110,253 and has fallen 87.3% since, to $14,010 in 2025. Among radiation oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$411,491in general payments, 2019–2025

Across 614 payments — averaging $670.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$154K
Novocure Inc.$107K
Novocure GmbH$80K
Telix Pharmaceuticals$59K
EMD Serono, Inc.$4K
AstraZeneca$1K
plus $6K from 42 others

$9,408in research payments, 2019–2025

Across 6 payments — averaging $1568.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novocure GmbH$8K
GT Medical Technologies, Inc$1K

What the payments were for

Consulting fees$116,03028%
Speaking & faculty fees$236,42257%
Travel & lodging$39,32010%
Food & beverage$19,7195%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	261	$154,148
Novocure Inc.	153	$106,986
Novocure GmbH	8	$80,250
Telix Pharmaceuticals	28	$59,322
EMD Serono, Inc.	5	$3,621
AstraZeneca(2 entities)	27	$1,359
Cardinal Health 414 LLC	1	$600
E.r. Squibb & Sons, L.L.C.	12	$526
Regeneron Healthcare Solutions, Inc.	8	$509
Karyopharm Therapeutics Inc.	7	$449
Sanofi	10	$380
Icotec Medical Inc.	3	$349
Johnson & Johnson(2 entities)	7	$321
Merck	6	$298
GT Medical Technologies, Inc	4	$245
Lilly USA, LLC	9	$243
Novartis	5	$203
Amgen	5	$176
Intuitive Surgical	2	$153
Galvanize Therapeutics, Inc	1	$136
Daiichi Sankyo Inc.	1	$103
Springworks Therapeutics, Inc.	4	$91
Rigel Pharmaceuticals, Inc.	4	$87
Pfizer	3	$64
Incyte Corporation	3	$63
Astellas Pharma US Inc	2	$56
Sobi, Inc	2	$54
Siemens Medical Solutions USA, Inc.	3	$53
ERBE USA Inc	1	$50
Eisai Inc.	2	$49
GE HealthCare	1	$48
Array Biopharma Inc	3	$48
Deciphera Pharmaceuticals Inc.	2	$44
Boehringer Ingelheim	3	$43
Seagen Inc.	2	$43
Kyowa Kirin, Inc.	2	$42
Blueprint Medicines Corporation	2	$41
Monteris Medical Corporation	2	$35
Pharmaessentia USA Corporation	1	$33
Blue Earth Diagnostics	1	$29
AbbVie	1	$23
Jazz Pharmaceuticals Inc.	1	$20
Foundation Medicine, Inc.	1	$20
Bristol Myers Squibb	1	$19
Puma Biotechnology, Inc.	1	$17
Bayer	1	$16
Helsinn Therapeutics (U.S.), Inc.	1	$15
Servier Pharmaceuticals LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$411,491 in reported general payments places this provider in the 95th percentile of 627 radiation oncology providers in California.

See all radiation oncology providers in California →

Medicare billing

Part B allowed, 2024

$120,375

Medicare patients

Services billed

899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	14	$298

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Palm Springs

Rakesh PatelLos Gatos$1.3M
Albert ChangLos Angeles$290K
Arya AminiDuarte$265K
Rizwan NuraniApple Valley$220K
Drew MoghanakiLos Angeles$183K
Jyoti MayadevSan Diego$170K
Percy LeeIrvine$125K
Felix FengSan Francisco$99K
Hyun KimDuarte$97K
Amar KishanLos Angeles$74K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →